Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company whose news flow centers on drug development milestones, scientific data presentations, financial updates, and capital markets activity. Public communications describe a focus on late-stage ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceutical programs for imaging and treating advanced cancers.
News items for Monopar commonly include clinical and scientific results, such as data from the ALXN1840-WD-204 copper balance study and pooled long-term neurological and safety analyses in Wilson disease. The company also reports on presentations at major medical meetings, including the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting and the American Neurological Association (ANA) Annual Meeting, as well as publications in peer-reviewed journals like the Journal of Hepatology.
Investors and observers can also find updates on radiopharmaceutical programs, including progress in Phase 1 imaging and therapeutic trials with MNPR-101-Zr and MNPR-101-Lu, and regulatory developments such as U.S. Food and Drug Administration authorization for an Expanded Access Program in advanced solid tumors. In addition, Monopar issues press releases on financial results, describing quarterly performance, research and development spending, and general and administrative expenses, alongside information on cash resources and capital-raising transactions.
Further topics in Monopar’s news include capital markets events, such as underwritten offerings of common stock and pre-funded warrants, share repurchase agreements with existing stockholders, and inclusion in the Russell 3000 and Russell 2000 indexes. Readers interested in MNPR news can use this page to follow these developments and review how the company describes the evolution of its Wilson disease and radiopharmaceutical programs over time.
Monopar Therapeutics (Nasdaq: MNPR) presented late-breaker data at EASL 2025 on ALXN1840, their drug candidate for Wilson disease. The analysis pooled data from three clinical trials (n=255) for efficacy and included a fourth trial for safety analysis (n=266), with median treatment durations of 2.63 and 2.58 years respectively.
Key findings showed sustained improvements in patient-reported and clinician-assessed symptoms (UWDRS), increased copper mobilization, better CGI-I scale results compared to standard care, and improvement in the New Wilson Index. The drug demonstrated strong safety with less than 5% of patients experiencing drug-related serious adverse events and no renal/urinary system SAEs. Patients reported higher convenience and effectiveness compared to standard treatment.
Monopar Therapeutics announced that their ALXN1840 drug candidate for Wilson disease has been selected for a prestigious late-breaker presentation at the EASL International Liver Congress 2025 in Amsterdam.
The presentation will focus on long-term efficacy and safety data of tiomolybdate choline (ALXN1840). The selection as a late-breaker abstract is significant, as these slots are reserved for the most recent and impactful research findings that could substantially influence the field.
The presentation titled "Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline" will be delivered by Dr. Karl Heinz Weiss on May 7, 2025. The poster will be made available on Monopar's website the same day.
This selection underscores the potential importance of the research, as late-breaker abstracts must meet strict criteria including presenting latest findings, demonstrating significant potential impact, and featuring prospective clinical studies.
Monopar Therapeutics (MNPR) reported its Q4 and full-year 2024 financial results, highlighting a significant year marked by key developments. The company raised over $55 million in Q4 2024 through public offerings and private placements. Cash position stood at $60.2 million as of December 31, 2024, expected to fund operations through 2026.
Key developments include the in-licensing of ALXN1840 for Wilson disease with plans to submit an NDA in early 2026, and the initiation of two first-in-human radiopharma Phase 1 trials. The company reported a Q4 2024 net loss of $10.9 million ($2.23 per share) compared to $1.8 million in Q4 2023. Full-year 2024 net loss was $15.6 million ($4.11 per share) versus $8.4 million in 2023.
R&D expenses increased to $9.9 million in Q4 2024, primarily due to ALXN1840 in-licensing costs. G&A expenses rose slightly to $1.2 million in Q4 2024 from $0.9 million in Q4 2023.
Monopar Therapeutics has joined Rosalind Franklin University's Helix 51 biomedical incubator community. The clinical-stage biotech company is developing personalized radiopharmaceuticals for cancer diagnosis and treatment, along with a late-stage drug for Wilson Disease.
The company will utilize Helix 51's labs and resources to advance its research objectives. Radiopharmaceuticals, which selectively target cancer cells with radioisotopes, are important in nuclear medicine, enabling precise diagnosis and treatment while minimizing damage to healthy tissues.
Helix 51 is Lake County, Illinois' only wet-and dry-lab based incubator, situated in a region hosting over 122 bioscience companies and 33,000 bioscience jobs. The facility is part of RFU's Innovation and Research Park, which offers research space and core facilities for drug, device, and diagnostic R&D.
Monopar Therapeutics (Nasdaq: MNPR) announced the pricing of a combined public offering and private placement totaling $40 million. The offering includes 798,655 shares of common stock at $23.79 per share and pre-funded warrants for 882,761 shares at $23.789 per warrant. The transaction, expected to close around December 23, 2024, features participation from notable investors including RA Capital Management, Janus Henderson Investors, Adage Capital Partners LP, and ADAR1 Capital Management. The company plans to use proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital.
Monopar Therapeutics (Nasdaq: MNPR) has announced the first-ever patient dosing of MNPR-101-Lu, a novel therapeutic radiopharmaceutical. The treatment combines MNPR-101 antibody targeting uPAR with lutetium-177 radioisotope. The first patient, who has metastatic pancreatic cancer, received the treatment under a compassionate use protocol in the US. The intravenous infusion was well-tolerated with no serious adverse reactions reported.
Prior to treatment, the patient's cancer was imaged using MNPR-101-Zr, showing uPAR expression. The company is currently conducting two Phase 1 clinical studies in Australia, evaluating MNPR-101-Zr for imaging and MNPR-101-Lu for treatment of advanced solid tumors.
Monopar Therapeutics (Nasdaq: MNPR) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. CEO Chandler Robinson will engage in a fireside chat and one-on-one meetings at the event. The presentation is scheduled for December 5, 2024, from 10:30-10:55 am Eastern Time at the Lotte New York Palace in New York. Monopar is a clinical-stage biotechnology company that develops innovative treatments for patients with unmet medical needs.
Monopar Therapeutics (Nasdaq: MNPR) reported Q3 2024 financial results and recent developments. Key highlights include the in-licensing of ALXN-1840, a late-stage Wilson disease drug candidate from Alexion, AstraZeneca Rare Disease. The company has two active radiophharma clinical trials enrolling patients with advanced solid cancers. A recent capital raise through a public offering generated net proceeds of $17.7 million. Q3 2024 showed a net loss of $1.3 million ($0.37 per share), compared to $2.0 million ($0.69 per share) in Q3 2023. Cash position was $6.0 million as of September 30, 2024, with current funds projected to sustain operations into first half of 2026.
Monopar Therapeutics (Nasdaq: MNPR) has closed its previously announced public offering of common stock, raising $19.2 million in gross proceeds. The shares were priced at $16.25 per share. Notable participants included Janus Henderson Investors and RA Capital Management. Rodman & Renshaw served as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. The offering was made through a shelf registration statement previously filed with the SEC.